Regenerative Medicine Archives – The Bio Connection

Biotechnology Heart Health Regenerative Medicine

Resolvin D-1 Limits Kidney Damage After Heart Attacks

February 21, 2018 TheBioConnection Comment(0)

A heart attack triggers an acute inflammatory response at the damaged portion of the heart’s left ventricle. If this acute inflammation lingers, it can lead to stretching of the ventricle and heart failure. The inflammation can claim another victim — the kidneys. New research shows that a bioactive compound called resolvin D-1, injected as a […]

Regenerative Medicine

US clinical trial puts Sernova one step closer to diabetes cure

February 12, 2018 TheBioConnection Comment(0)

(Aheadofthehead.com) Last week I read a shocking post on one of my social media feeds. The author was a diabetic who displayed a photo of a bill from Walgreens and two boxes of insulin. Three vials of Humalog cost the man $807.96, which lasts one month. At that rate, his annual insulin tab is just […]

A 150-year-old drug might improve radiation therapy for cancer October 17, 2018
A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more sensitive to radiation therapy. Researchers found that the drug papaverine inhibits the respiration of mitochondria, the oxygen-consuming and energy-making components of cells, and sensitizes model tumors to radiation. They found that the drug does not affect the radiation […]
Vast leukemia dataset could help researchers match therapies to patients October 17, 2018
Data on the molecular makeup and drug sensitivity of hundreds of patient samples could accelerate progress against the aggressive blood cancer acute myeloid leukemia.
Breastfeeding protects infants from antibiotic-resistant bacteria October 17, 2018
A new study shows that infants that are breastfed for at least six months have less antibiotic-resistant bacteria in their gut compared with babies breastfed for a shorter time. On the other hand, antibiotic use by mothers increases the number of antibiotic-resistant bacteria in infants.
Lymphatic system, key player in human health October 16, 2018
Defects in the lymphatic system have been linked to a wide range of health consequences, but new findings of how the system works could lead to future therapies.
Age-related increase in estrogen may cause common men's hernia October 16, 2018
An age-related increase in estrogen may be the culprit behind inguinal hernias, a condition common among elderly men that often requires corrective surgery. Men could be treated with hormone inhibitor to strengthen muscle, the researcher suggests.
This RNA-based technique could make gene therapy more effective October 16, 2018
Biological engineers have devised a way to regulate the expression of messenger RNA once it gets into cells, giving them more precise control over gene therapy treatments for cancer and other diseases.
A bad influence: Interplay between tumor cells and immune cells October 16, 2018
Research has yielded new insights into the environment surrounding different types of lung tumors, and described how these complex cell ecosystems may in turn ultimately affect response to treatment.
Automated system identifies dense tissue, a risk factor for breast cancer, in mammograms October 16, 2018
Researchers have developed an automated model that assesses dense breast tissue in mammograms -- which is an independent risk factor for breast cancer -- as reliably as expert radiologists. This marks the first time a deep-learning model of its kind has successfully been used in a clinic on real patients, according to the researchers. With […]
Diets rich in fish oil could slow the spread and growth of breast cancer cells October 16, 2018
Omega-3 fatty acids, such as those typically contained in fish oil, may suppress the growth and spread of breast cancer cells in mice.
New way to determine whether metastatic cancer cells in breast cancer patients are dormant or soon to turn deadly October 16, 2018
For the first time ever, researchers have identified a protein as a marker that can indicate whether a cancer patient will develop a recurrence of lethal, metastatic cancer.

Dr. Reddy's expects to file BLA on its anti-cancer T-cell lymphoma drug end of 2019 October 17, 2018
Dr. Reddy’s Laboratories Ltd (NYSE:RDY) Senior Vice President Anil Namboodiripad spoke with Proactive Investors’ Christine Corrado at the Bio Investor Forum in San Francisco. The drug manufacturer’s areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
Heidelberg Pharma looks to file IND Q2 2019 for its drug to treat cancer tumors October 17, 2018
Heidelberg Pharma AG (ETR:WL6) CEO Jan Schmidt-Brand spoke with Christine Corrado at the Bio Investor Forum in San Francisco. Heidelberg Pharma is a drug development company, which provides pre-clinical drug discovery and development services for the development of anti-cancer and anti-inflammatory drugs to pharmaceutical and biotechnology industries.
Mezzion Pharma expects topline data end of Q1 2019 October 17, 2018
Erik Emerson from Mezzion Pharma Co Ltd (KOSDAQ:140410) sat down with Proactive Investors' Christine Corrado at the Bio Investor Forum in San Francisco. The South Korean company is developing its drug Udenafil to treat single ventricle heart disease.
Aurora Cannabis granted sales license by Health Canada on first day of legalized marijuana October 17, 2018
Company has begun production of softgel capsules for adult consumer markets
How Genprex took an abandoned pipeline drug and turned it into Oncoprex, an innovative treatment for non-small cell lung cancer October 17, 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
InMed Pharmaceuticals partners with the National Research Council of Canada October 17, 2018
InMed Pharmaceuticals Inc (OTCMKTS:IMLFF) CEO Eric Adams spoke with Christine Corrado at the Bio Investor Forum in San Francisco. InMed Pharmaceuticals specializes in developing novel therapies through research into the pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary bioinformatics database drug/disease targeting tool, cannabinoid biosynthesis technology and drug development pipeline are strong […]
MaxCyte doses first ovarian cancer patient in phase 1 clinical trial October 17, 2018
MaxCyte Inc (LON:MXCT) CEO Doug Doerfler sat down with Proactive Investors' Christine Corrado at the Bio Investor Forum in San Francisco. Over the summer, the US FDA gave the company investigational new drug clearance for MCY-M11, a chimeric antigen receptor that targets solid tumours. Two weeks ago, the company began dosing its first patient.
Dyadic International Inc stock ticks up on partnership announcement October 17, 2018
Dyadic International Inc (OTCQX:DYAI) CEO Mark Emalfarb sat down with Proactive Investors' Christine Corrado at the Bio Investor Forum in San Francisco. Proactive previously interviewed Ping Rawson about the company at the MicroCap Conference in October. Dyadic International is a global biotechnology company focused on further improving and applying the proprietary C1 expression system to […]
Rexahn Pharmaceuticals stock sinks after announcing direct share offering October 17, 2018
The offering is expected to generate gross proceeds of $5.7 million
Amryt Pharma’s Lojuxta ‘bad’ cholesterol treatment to be made available in France in early 2019 October 17, 2018
The approval from French regulators means Lojuxta will soon be available in all five of the EU’s largest markets

STAT Plus: Pharmalittle: Teva faces setback in new migraine drug market; prices for valsartan jump in the U.S. October 17, 2018
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember, there are only a few more days until the weekend arrives.…
STAT Plus: Minnesota becomes first state to sue major insulin makers over price-gouging October 16, 2018
In the latest sign of anger over the cost of insulin, the Minnesota attorney general filed a lawsuit accusing the three largest manufacturers with deceptively raising prices, the first state…
STAT Plus: U.S. antitrust regulators are investigating a key supplier of radiology medicines October 16, 2018
A key supplier of radiology medicines in the U.S. is being investigated by antitrust regulators over its business practices.
STAT Plus: Pharmalittle: Legal issues loom over disclosing prices in TV ads; AstraZeneca halts U.K. investment over Brexit worries October 16, 2018
AstraZeneca has suspended investments in the U.K. due to the lack of clarity over the country's looming departure from the European Union.
STAT Plus: A cost-effectiveness watchdog may charge drug makers for ‘early scientific advice’ October 15, 2018
An ICER spokesman said "we would only do so in a manner that would preserve ICER’s independence and integrity."
STAT Plus: Controversy over a Sanofi dengue vaccine caused a crisis of confidence in the Philippines October 15, 2018
After a recent scandal in the Philippines over a Sanofi dengue vaccine, public confidence in vaccines in general has plummeted in the country, according to a new survey.
STAT Plus: Pharmalittle: Trump to require drug prices in ads; Europe cracks down on valsartan ingredients maker October 15, 2018
Europe cracks down on valsartan ingredients maker in China.
STAT Plus: Merck scraps plans to sell a biosimilar version of Lantus as the insulin market gets crowded October 12, 2018
In an unexpected move, Merck (MRK) scrapped plans to market a biosimilar version of the widely used Lantus insulin only a year after winning tentative U.S. regularly approval. The decision…
STAT Plus: Up and down the ladder: The latest comings and goings October 12, 2018
Hired someone new and exciting? Promoting a rising star? Finally solved that hard-to-fill spot?
STAT Plus: Pharmalittle: FDA approves a record number of generics; Bristol-Myers’ Opdivo fails lung cancer study goal October 12, 2018
As of November, specialist clinicians in the U.K. will be able to prescribe cannabis-derived medicinal products for the first time after a change in the law.

Anixa Biosciences Releases Data Presented at AACR Artificial Intelligence Conference
Anixa Biosciences presented the results from its ongoing study utilizing Cchek™.
ArQule to Report Third Quarter 2018 Financial Results on October 31, 2018
ArQule, Inc. today announced it will report financial results for the third quarter of 2018 before the market opens on Wednesday, October 31, 2018.
Sleep Well, Wake up Alert: Eisai and Purdue's Lemborexant Positive in Phase III Trial for Insomnia
Eisai Co. and Purdue Pharma announced topline results from their SUNRISE 2 Phase III clinical trial of lemborexant for sleep-wake disorders.
Acticor Biotech Raises €15.3M In a Series B Financing
New financing will enable the company to launch shortly the first Phase II clinical trial of its lead candidate ACT017 inhibiting GPVI in acute ischemic stroke.
Biogen and Samsung Bioepis Announce European Launch of IMRALDI™(adalimumab), Solidifying Leadership in European Anti-TNF Market
IMRALDITM (adalimumab), a biosimilar referencing HUMIRA® i, is the third anti-TNF biosimilar developed by Samsung
Ology Bioservices Strengthens Management Team with Addition of Timothy Cooke, Ph.D. as Senior Vice President of Commercial Business
Ology Bioservices, Inc. announced today that industry veteran Timothy Cooke, Ph.D., has joined the Company as Senior Vice President of Commercial Business.
Medivir Scales Back Research Costs to Focus on Clinical Development
Medivir AB announced today plans to reduce activities not critical to its development pipeline of drug candidates as part of its enhanced focus on clinical stage projects.
ImmunoCellular Announces Receipt of Notice of Noncompliance with The NYSE American Continued Listing Standards
ImmunoCellular Therapeutics, Ltd. today announced that on October 16, 2018, the Company received notice from the NYSE American LLC ("NYSE American" or the "Exchange") that it has determined to commence proceedings to delist the Company's Common Stock (NYSE American: IMUC) and Listed Common Stock Warrants (NYSE American: IMUC.WS) from the Exchange.
BioInvent Embarks on Intensive Investor Meeting Program in the U.S., Europe, and Israel, and Posts Updated Presentation on Corporate Website
BioInvent International AB today announced that in connection with its intensive upcoming investor meeting program it has published the updated corporate presentation on its website.
FDA Approves Pfizer’s Talzenna for Breast Cancer
The U.S. FDA approved Pfizer’s PARP inhibitor, Talzenna (talazoparib), for patients with a germline BRCA-mutated (gBRCAm), HER2-negative breast cancer. The agency also approved Myriad Genetics’ diagnostic assay to identify the mutation.